Citigroup Portfolio holdings
Citigroup Inc., formed in 1998 through the landmark merger of Citicorp and Travelers Group, with roots tracing back to the 1812 founding of City Bank of New York, is a global financial powerhouse headquartered in New York City, managing trillions in assets. Operating in over 160 countries, Citigroup offers a broad spectrum of services, including consumer banking (via Citibank), investment banking, wealth management, and trading, serving millions of retail customers and major corporations, governments, and institutions worldwide. Under CEO Jane Fraser since 2021—the first woman to lead a major U.S. bank—Citigroup has focused on streamlining operations, exiting consumer banking in 13 markets to bolster its institutional and wealth management focus, while navigating post-2008 regulatory scrutiny and fines. Known for its vast global footprint and resilience through crises, Citigroup remains a key player in international finance, blending retail accessibility with high-stakes capital markets expertise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$349M |
| 2 |
Vanguard S&P 500 ETF
VOO
|
+$305M |
| 3 |
iShares Gold Trust
IAU
|
+$282M |
| 4 |
State Street SPDR S&P Regional Banking ETF
KRE
|
+$269M |
| 5 |
Blackrock
BLK
|
+$267M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$625M |
| 2 |
NVIDIA
NVDA
|
+$604M |
| 3 |
Tesla
TSLA
|
+$576M |
| 4 |
Microsoft
MSFT
|
+$552M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.55% |
| 2 | Financials | 7.82% |
| 3 | Consumer Discretionary | 7.65% |
| 4 | Communication Services | 5.12% |
| 5 | Healthcare | 5.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3726
Hagerty
HGTY
$1.32B
| $310K | ﹤0.01% |
30,641
+26,929
| +725% | +$251K |
|
|
EU
3727
enCore Energy
EU
$221M
| $309K | ﹤0.01% |
108,506
-20,281
| -16% | -$36.5K |
|
3728
Invesco S&P 500 Pure Growth ETF
RPG
$2.09B
| $308K | ﹤0.01% |
6,723
+802
| +14% | +$32.9K |
|
3729
JPMorgan Nasdaq Equity Premium Income ETF
JEPQ
$41.9B
| $306K | ﹤0.01% |
+5,620
| New | +$290K |
|
3730
AMC Global Media
AMCX
$496M
| $305K | ﹤0.01% |
48,615
-19,316
| -28% | -$122K |
|
3731
Daily Journal
DJCO
$828M
| $304K | ﹤0.01% |
721
-600
| -45% | -$240K |
|
3732
Fulgent Genetics
FLGT
$513M
| $304K | ﹤0.01% |
15,280
-14,452
| -49% | -$282K |
|
3733
Taysha Gene Therapies
TSHA
$1.92B
| $301K | ﹤0.01% |
130,317
-2,877
| -2% | -$6.25K |
|
3734
iShares 0-5 Year Investment Grade Corporate Bond ETF
SLQD
$2.38B
| $301K | ﹤0.01% |
5,949
+7
| +0.1% | +$351 |
|
3735
Tronox
TROX
$958M
| $300K | ﹤0.01% |
59,149
-37,934
| -39% | -$207K |
|
3736
Genie Energy
GNE
$386M
| $300K | ﹤0.01% |
11,147
-4,378
| -28% | -$83.9K |
|
3737
Olema Pharmaceuticals
OLMA
$920M
| $300K | ﹤0.01% |
70,331
+39,340
| +127% | +$175K |
|
3738
Prothena Corp
PRTA
$466M
| $299K | ﹤0.01% |
49,303
-16,523
| -25% | -$124K |
|
3739
CALL
Sarepta Therapeutics
SRPT
$1.95B
| $299K | ﹤0.01% |
17,500
| – | – |
|
|
3740
PUT
Sarepta Therapeutics
SRPT
$1.95B
| $299K | ﹤0.01% |
17,500
| – | – |
|
|
VMEO
3741
DELISTED
Vimeo
VMEO
| $298K | ﹤0.01% |
73,848
-48,223
| -40% | -$223K |
|
3742
Stoke Therapeutics
STOK
$2.02B
| $298K | ﹤0.01% |
26,230
-48,390
| -65% | -$459K |
|
3743
Zai Lab
ZLAB
$2.92B
| $298K | ﹤0.01% |
8,512
+1,393
| +20% | +$45.8K |
|
|
ELP
3744
DELISTED
Companhia Paranaense de Energia (COPEL)
ELP
| $297K | ﹤0.01% |
32,566
-5,350
| -14% | -$44.9K |
|
3745
Agilon Health
AGL
$1.49B
| $297K | ﹤0.01% |
5,162
-4,574
| -47% | -$367K |
|
3746
iShares Global Infrastructure ETF
IGF
$10.7B
| $296K | ﹤0.01% |
+5,000
| New | +$285K |
|
3747
Cimpress
CMPR
$2.37B
| $295K | ﹤0.01% |
6,281
-6,712
| -52% | -$293K |
|
3748
Evolv Technologies
EVLV
$1.04B
| $295K | ﹤0.01% |
47,295
-56,988
| -55% | -$264K |
|
3749
Seneca Foods Class A
SENEA
$1.31B
| $295K | ﹤0.01% |
2,905
-2,000
| -41% | -$180K |
|
3750
ProShares Short VIX Short-Term Futures ETF
SVXY
$234M
| $294K | ﹤0.01% |
+6,909
| New | +$273K |
|
Similar funds
Citigroup's Q2 2025 Portfolio in Review
As of Q2 2025, Citigroup held 6,003 positions worth $204B, up 4.1% from $196B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Citigroup withdrew a net $14.6B in Q2 2025, closing 377 positions and reducing 2,974 holdings. Its most notable exit was James Hardie Industries, an estimated $125M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 18% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Citigroup opened a new position in Amrize Ltd worth $114M.
- Citigroup's largest Q2 2025 buy was Amrize Ltd: 2,294,135 shares worth $114M.
- Citigroup added most to Bank of America in Q2 2025, an estimated $349M increase.
- Citigroup's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $625M.
- Citigroup fully exited James Hardie Industries in Q2 2025, selling an estimated $125M.
- Citigroup's ten largest holdings make up 20% of its $204B portfolio in Q2 2025.
- Citigroup opened 468 new positions and closed 377 in Q2 2025.
- Citigroup's portfolio value rose 4.1% quarter-over-quarter to $204B.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.